Medical AI Alliance
← Company Index
Biotech & Drug DiscoveryKOSDAQ 3890304 approvals

GENINUS Inc.

Official website

GENINUS operates the IntelliMed, MEDINSIGHT, and SPACEINSIGHT data analytics platforms for precision medicine and drug development.

As of 2026-10-11, GENINUS Inc. has 4 Korean MFDS device approvals, 78 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Founded in 2018 and listed on KOSDAQ in 2021, GENINUS is a data analytics platform company supporting precision medicine and drug development. Its core businesses are IntelliMed, which integrates single-cell and spatial transcriptomic data to discover novel drug targets, MEDINSIGHT, an AI-based digital pathology platform automating pathology image analysis, and SPACEINSIGHT, which integrates spatial omics and pathology imaging analysis. The company obtained GCLP certification in October 2024 and CAP certification in December 2020 (valid through December 2026), with global and domestic large pharmaceutical companies developing anticancer, ADC, and immuno-oncology drugs as key customers.

Products & technology

  • IntelliMedPlatform integrating single-cell transcriptomic, spatial transcriptomic, and spatial proteomic data to discover novel drug targets and combinations
  • MEDINSIGHTAI-based digital pathology platform automating cell type annotation, tumor microenvironment quantification, and biomarker expression analysis from H&E and IHC pathology images
  • SPACEINSIGHTPlatform integrating spatial transcriptomic, spatial proteomic, and pathology image data to assess tumor microenvironment structure, cell-cell interactions, and spatial target uniformity

Regulatory approvals

data.go.kr

4 Korean MFDS device approvals · 2022–2026

  • MFDSIVD reagents for cancer related gene2026-01-08
    Product approval · Class 3체외 제허 26-20 호
  • MFDSIVD reagents for cancer related gene2025-11-27
    Product approval · Class 3체외 제허 25-801 호
  • MFDSIVD reagents for cancer related gene2025-11-27
    Product approval · Class 3체외 제허 25-800 호
  • MFDSIVD reagents for cancer related geneRevoked2022-10-04
    Product approval · Class 3체외 제허 22-661 호

Publications

PubMed · affiliation-matched
Show 68 more publications

Patents

KIPRIS · applicant-matched
Show 31 more patents

AI reads

MAA server logs · IP-verified
81
Times AI engines pulled GENINUS Inc.'s records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

8
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

73
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

14
live 2
Last 7 days
66
live 7
Last 30 days
81
live 8
All time
  • OpenAIChatGPT-Userlive8
  • OpenAIOAI-SearchBot63
  • PerplexityPerplexityBot4
  • GoogleGoogleOther2
  • MicrosoftBingbot2
  • AnthropicClaudeBot2

Measured since Aug 27, 2026 · 5 AI engines · last read Oct 10, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for GENINUS Inc. and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview · R&D. Send us materials and we will add them

Companies approved for the same productsBiotech & Drug Discovery

Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.

Gencurix Inc.1 shared

Founded 2011, KOSDAQ-listed 2020, Gencurix develops liquid-biopsy diagnostics: breast cancer prognosis and lung/colorectal companion tests.

Eone Diagnomics Genome Center Co., Ltd.1 shared

EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.

NGeneBio Co., Ltd.1 shared

KOSDAQ-listed precision-diagnostics company manufacturing genomic diagnostic reagents and developing related software.

BIONEERCORPORATION1 shared

Bioneer, founded in 1992 and KOSDAQ-listed in 2005, provides gene analysis equipment, molecular diagnostics, and RNAi drug development.

HLB PANAGENE Co., LTD.1 shared

Founded in 1976 and KOSDAQ-listed in 2000, HLB PANAGENE develops PNA-based molecular diagnostic and diagnostic automation products.

Optipharm.CO.,LTD1 shared

Optipharm, founded in 2000 and KOSDAQ-listed in 2018, provides animal disease diagnostics, animal medicine, and biotech.

GC Medical Science Corporation1 shared

GC Medical Science Corporation, KOSDAQ-listed since 2014, operates diagnostic reagent, blood glucose, and hemodialysis solution businesses.

LabGenomics. Co., Ltd.1 shared

KOSDAQ-listed molecular genetic diagnostics company providing NGS-based non-invasive prenatal testing (NIPT) under the MomGuard brand.

SEEGENE, INC.1 shared

Founded in 2000 and KOSDAQ-listed in 2010, Seegene develops syndromic multiplex PCR molecular diagnostic reagents.

Genomictree Inc.1 shared

Cancer molecular diagnostics company behind the EarlyTect-C stool-based colorectal cancer test using the SDC2 methylation biomarker.

AHNLAB,INC.100

KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.

Inventage Lab Inc.100

Drug delivery system company behind the long-acting injectable platform IVL-DrugFluidic and the LNP delivery platform IVL-GeneFluidic.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition